Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth

Cnbc · May 05, 2026 · 766 words · By Annika Kim Constantino

headphones Listen to the eFinder podcast briefing

Generate a natural audio summary of this story

Daily briefing

What to know about Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth

Pfizer on Tuesday posted first-quarter earnings and revenue that topped estimates and reaffirmed its 2026 outlook, as its recently launched and acquired products showed growth.

Claims checked 23

Techniques found 0

Topics 0

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center75%

Right25%

4 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Pfizer on Tuesday posted first-quarter earnings and revenue that topped estimates and reaffirmed its 2026 outlook, as its recently launched and acquired products showed growth.

Why it matters

Older top-selling drugs, including its blood thinner Eliquis, also helped drive demand in the quarter and offset the decline in revenue from Pfizer's Covid vaccine and antiviral pill to treat the virus, Paxlovid.

Common ground

Still, the company is slated to face the loss of exclusivity of some older drugs over the next few years, which is expected to weigh on sales.

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

Follow-up questions

What concrete event or decision sits underneath the headline: Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth?
What evidence would most clearly confirm or weaken the claim that comes in higher than the $145.1 million that analysts were expecting [for RSV vaccine]?
What should readers watch for in the next update to know whether the story is changing?

open_in_new Read the original article: https://www.cnbc.com/2026/05/05/pfizer-pfe-earnings-q1-2026.html

fact_checkClaims Checked

eFinder analyzed this article and checked 23 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

schedule Pending 13

check_circle Corroborated 10

schedule

Claim 1: “comes in higher than the $145.1 million that analysts were expecting [for RSV vaccine]”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 2: “expecting full-year adjusted profit to come in between $2.80 and $3 per share, and revenue to total $59.5 billion to $62.5 billion [for 2026]”

CORROBORATED

Although the specific 'evidence' section for claim 9 was empty, the evidence provided for claim 1 and 7 explicitly lists the 2026 guidance as adjusted profit between $2.80 and $3 per share and revenue between $59.5 billion and $62.5 billion.

schedule

Claim 3: “Pfizer entered into settlement agreements with three generic drug manufacturers that effectively extend the company's U.S. patent protection for Vyndamax until June 1, 2031.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 4: “Eliquis generated $2.17 billion in sales for the quarter, up 13% from the year-ago period.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 5: “Earnings per share: 75 cents adjusted vs. 72 cents expected”

CORROBORATED

Multiple sources confirm the adjusted EPS was 75 cents versus an expected 72 cents.

travel_explore

web search NEUTRAL — Pfizer was founded in 1849 as Charles Pfizer & Company by Charles Pfizer and Charles F. Erhart, [6][7] two cousins who had immigrated to the United States from Ludwigsburg, Germany. The business produ…
https://en.m.wikipedia.org/wiki/Pfizer

travel_explore

web search NEUTRAL — Pfizer RxPathways connects eligible patients to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings.
https://www.pfizer.com/

travel_explore

web search NEUTRAL — Find the latest Pfizer Inc. (PFE) stock quote, history, news and other vital information to help you with your stock trading and investing.
https://finance.yahoo.com/quote/PFE/?fr=sycsrp_catchall

schedule

Claim 6: “surpassing the $542.3 million that analysts were expecting [for Padcev]”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 7: “2025 revenue of $62.6 billion”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 8: “That compares with net income of $2.97 billion, or 52 cents per share, during the same period a year ago.”

CORROBORATED

Multiple sources confirm the prior year's net income was $2.97 billion or 52 cents per share.

travel_explore

web search NEUTRAL — That compares with net income of $2.97 billion, or 52 cents per share, during the same period a year ago.Pfizer reaffirmed its 2026 outlook, expecting 2026 adjusted profit to come in between $2.80 and…
https://www.topologypro.one/pfizer-tops-wall-street-estimate…

travel_explore

web search NEUTRAL — net income for the twelve months ending March 31,a 139.97% increase from...
https://www.macrotrends.net/stocks/charts/PFE/pfizer/net-inc…

travel_explore

web search NEUTRAL — Net income came in at $2.69 billion, down from $2.97 billion a year ago. Still profitable, just not at the same level. Looking ahead, Pfizer isn’t changing its tune. The company reaffirmed its 2026 ou…
https://wyomingstarnews.org/2026/05/05/pfizer-beats-expectat…

schedule

Claim 9: “Targeted cancer drug Padcev booked $591 million in revenue, up 39% from the same period a year ago”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 10: “its recent $10 billion acquisition of the obesity biotech Metsera”

CORROBORATED

Three independent sources (Nikkei Asia, Reuters, and another news source) confirm the $10 billion acquisition of Metsera.

travel_explore

web search NEUTRAL — Pfizer acquires Metsera in $10 billion deal after competitive bidding with Novo Nordisk.Healthy Returns: What to know about Pfizer and Novo Nordisk’s bidding war over obesity biotech Metsera.
https://news.google.com/stories/CAAqNggKIjBDQklTSGpvSmMzUnZj…

travel_explore

web search NEUTRAL — Pfizer will acquire Metsera at a price of up to $86.25 a share, Metsera said in a statement. That was slightly higher than Novo Nordisk’s last offer on Tuesday, which valued Metsera at around $10 bill…
https://www.nytimes.com/2025/11/08/business/metsera-pfizer-m…

travel_explore

web search NEUTRAL — (Reuters) -- Obesity drug developer Metsera has accepted Pfizer's $10 billion acquisition offer, ending a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordi…
https://asia.nikkei.com/business/business-deals/pfizer-seals…

schedule

Claim 11: “Analysts expected $1.96 billion in revenue [for Eliquis], according to StreetAccount estimates.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 12: “Pfizer's vaccine against respiratory syncytial virus... booked $180 million in sales for the first quarter. That's up 37% from the year-earlier period”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 13: “Sales of recently launched and acquired products grew 22% operationally during the quarter, Pfizer said.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 14: “Pfizer reaffirmed its 2026 outlook”

CORROBORATED

Three separate web sources confirm that Pfizer reaffirmed its full-year 2026 financial guidance/outlook.

travel_explore

web search NEUTRAL — Pfizer reaffirmed its full-year 2026 revenue guidance of $59.5 billion to $62.5 billion and adjusted EPS of $2.80 to $3, compared with analyst estimates of $2.96.
https://finance.yahoo.com/sectors/healthcare/articles/pfizer…

travel_explore

web search NEUTRAL — NEW YORK, Tuesday, February 3, 2026 — Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2025 and reaffirmed its full-year 2026 financial guidance(1) provided on Decem…
https://s206.q4cdn.com/795948973/files/doc_financials/2025/q…

travel_explore

web search NEUTRAL — Pfizer Inc (NYSE:PFE, XETRA:PFE) reported first-quarter 2026 revenue and adjusted profit above Wall Street expectations on Tuesday, driven by strong growth in its launched and acquired products, as th…
https://www.alphaspread.com/market-news/earnings/pfizer-beat…

check_circle

Claim 15: “Pfizer reported revenue of $14.45 billion for the first quarter, up 5% from the same period a year ago.”

CORROBORATED

Multiple sources confirm the first-quarter revenue of $14.45 billion and the 5% year-over-year increase.

travel_explore

web search NEUTRAL — Pfizer reported revenue of $14.45 billion for the first quarter, up 5% from the same period a year ago.The company also pointed to another roughly $1.5 billion year-over-year expected drop in sales du…
https://www.topologypro.one/pfizer-tops-wall-street-estimate…

travel_explore

web search NEUTRAL — The American pharmaceutical giant Pfizer reports first-quarter revenue of $14.4 billion, an increase of just over 5 percent compared with the same quarter last year. That was better than expected. Ana…
https://swedenherald.com/article/pfizer-firstquarter-revenue…

travel_explore

web search NEUTRAL — Revenue landed at $14.45 billion, also ahead of expectations and up about 5% from a year ago.Sales of Pfizer’s Covid vaccine dropped sharply, down nearly 60% year over year to $232 million. Its antivi…
https://wyomingstarnews.org/2026/05/05/pfizer-beats-expectat…

check_circle

Claim 16: “The company booked net income of $2.69 billion, or 47 cents per share.”

CORROBORATED

Two independent sources confirm net income of $2.69 billion or 47 cents per share.

travel_explore

web search NEUTRAL — net income for the twelve months ending March 31,a 139.97% increase from...
https://www.macrotrends.net/stocks/charts/PFE/pfizer/net-inc…

travel_explore

web search NEUTRAL — Pfizer reported revenue of $14.45 billion for the first quarter, up 5% from the same period a year ago. Sales increases for key products helped to counteract struggles in its Covid business. The compa…
https://eng.pressbee.net/show4668006.html?title=pfizer-tops-…

travel_explore

web search NEUTRAL — The drugmaker posted first-quarter earnings of 75 cents a share, topping forecasts of 72 cents. Revenue landed at $14.45 billion, also ahead of expectations and up about 5% from a year ago.Net income …
https://wyomingstarnews.org/2026/05/05/pfizer-beats-expectat…

check_circle

Claim 17: “Excluding certain items, including restructuring charges and costs associated with intangible assets, Pfizer posted earnings per share of 75 cents for the quarter.”

CORROBORATED

While the specific 'evidence' section for claim 8 was empty, the evidence provided for claim 0 and 2 explicitly confirms the adjusted EPS was 75 cents, which aligns with the non-GAAP description in claim 8.

check_circle

Claim 18: “Revenue: $14.45 billion vs. $13.79 billion expected”

CORROBORATED

Multiple sources confirm revenue of $14.45 billion against an expected $13.79 billion (or approximately $13.8 billion).

travel_explore

web search NEUTRAL — Pfizer crushed first-quarter expectations on stronger drug sales. Adjusted EPS landed at 75 cents on $14.45 billion in revenue, beating Wall Street's 72-cent and $13.79 billion estimates, and the comp…
https://www.openingbelldailynews.com/p/earnings-stock-market…

travel_explore

web search NEUTRAL — Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.
https://investors.pfizer.com/Investors/Financials/Quarterly-…

check_circle

Claim 19: “Pfizer on Tuesday posted first-quarter earnings and revenue that topped estimates”

CORROBORATED

Multiple independent sources (The Motley Fool, Investing.com, and another news source) confirm that Pfizer's Q1 earnings and revenue exceeded analyst estimates.

travel_explore

web search NEUTRAL — On the bottom line, first quarter reported diluted earnings per share was $0.47, and adjusted diluted earnings per share was $0.75, also exceeding our expectations.
https://www.fool.com/earnings/call-transcripts/2026/05/05/pf…

travel_explore

web search NEUTRAL — The pharmaceutical giant posted revenue of $14.5 billion for the quarter ended March 31, up 5% from a year earlier and ahead of analyst estimates of $13.84 billion. Adjusted earnings per share came in…
https://www.proactiveinvestors.com/companies/news/1091752/pf…

travel_explore

web search NEUTRAL — Investing.com -- Pfizer Inc. (NYSE:PFE) reported first-quarter earnings that exceeded Wall Street expectations, driven by strong performance from its recently launched and acquired products portfolio.
https://finance.yahoo.com/sectors/healthcare/articles/pfizer…

schedule

Claim 20: “The vaccine raked in $232 million in revenue for the quarter, down 59% from the same period a year ago”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 21: “Analysts were expecting sales of $445.9 million and $286.2 million, respectively, for the two products [Covid vaccine and Paxlovid].”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 22: “declining sales of its Covid vaccine and Paxlovid, which it expects to fall by about $1.5 billion year over year to $5 billion”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 23: “Paxlovid sales fell 62% to $186 million”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.